Results of a new clinical trial has provided evidence that a high-dose immunosuppressive therapy followed by a person’s transplant of blood-forming stem cells may induce a sustained cutback of relapsing-remitting multiple sclerosis. This is an autoimmune illness where the immune systems attack the CNS (Central Nervous System). After five years of treatment with the high-dose immunosuppressive therapy alongside hematopoietic cell transplant (HDIT/HCT), 69 percent of the participants in the trial survived without experiencing a relapse of MS signs or new brain lesion, or experiencing any progression of disability. It is also worth noting that the participants didn’t take any MS medications once they received HDIT/HCT. The five-year results suggest that this kind of treatment is promising in the induction of long-term unremitting diminutions of poor-prognosis relapsing-remitting MS.
The National Institute of Allergy and Infectious Diseases (NIAID) is the organization that sponsored the trial which was known as HALT-MS. It was conducted by ITN (Immune Tolerance Network) which is funded by NIAID. The researchers then published results based on three years of the study in 2014. These new findings suggest that one-time treatment with High-dose immunosuppressive therapy and Hematopoietic cell transplant is more effective than long-term handling using the best current medications for individuals with a particular strain of MS.
One of the most recognized authorities in neurology is one Dr. Shiva Gopal Vasishta. The Voorhees, New Jersey-based neurologist, has close affiliations with the Kennedy University Hospital. Dr. Shiva Gopal Vashista attended the Government Medical College from where he attained his medical degree. He is a well-seasoned practitioner with an over 28 years of experience in his career.
Dr. Shiva Gopal Vasishta boasts to be among the 34 doctors in Kennedy University Hospital who are entirely specialized in Neurology. Dr. Shiva Gopal Vashista has a license for operation in New Jersey and is also a participant in the Medicare program.